Skip to main content
. 2022 Sep 30;20(3):e31. doi: 10.5808/gi.22012

Fig. 1.

Fig. 1.

Analysis of expression of CXCL10 and TMPRSS2 in different cancer by using TIMER. (A) Different level of CXCL10 mRNA expression is shown in multiple cancer studies whereas the overexpression of CXCL10 in PRAD, is marked in the red box. (B) Different level of TMPRSS2 mRNA expression is shown in multiple cancer studies whereas the overexpression of TMPRSS2 in PRAD is marked in the red box. *p < 0.05, **p < 0.01, ***p < 0.001. CXCL10, C-X-C motif 10; TMPRSS2, transmembrane protease serine subtype 2; ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasiva carcinoma; CESC, cervical squamous cell carcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, diffuse Large B-cell Lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; HPV, human papillomavirus; KICH, kidney chromophobe; KIRC, kidney clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular r germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma.